195 related articles for article (PubMed ID: 31548239)
1. Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression.
Chandrasekaran S; Sasaki M; Scharer CD; Kissick HT; Patterson DG; Magliocca KR; Seykora JT; Sapkota B; Gutman DA; Cooper LA; Lesinski GB; Waller EK; Thomas SN; Kotenko SV; Boss JM; Moreno CS; Swerlick RA; Pollack BP
Mol Cancer Res; 2019 Dec; 17(12):2395-2409. PubMed ID: 31548239
[TBL] [Abstract][Full Text] [Related]
2. Metabolic stress in cancer cells induces immune escape through a PI3K-dependent blockade of IFNγ receptor signaling.
Marijt KA; Sluijter M; Blijleven L; Tolmeijer SH; Scheeren FA; van der Burg SH; van Hall T
J Immunother Cancer; 2019 Jun; 7(1):152. PubMed ID: 31196219
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor inhibition augments the expression of MHC class I and II genes.
Pollack BP; Sapkota B; Cartee TV
Clin Cancer Res; 2011 Jul; 17(13):4400-13. PubMed ID: 21586626
[TBL] [Abstract][Full Text] [Related]
4. Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line.
Dovhey SE; Ghosh NS; Wright KL
Cancer Res; 2000 Oct; 60(20):5789-96. PubMed ID: 11059775
[TBL] [Abstract][Full Text] [Related]
5. Stat1 alpha expression is involved in IFN-gamma induction of the class II transactivator and class II MHC genes.
Lee YJ; Benveniste EN
J Immunol; 1996 Aug; 157(4):1559-68. PubMed ID: 8759739
[TBL] [Abstract][Full Text] [Related]
6. Targeted disruption of PI3K/Akt/mTOR signaling pathway, via PI3K inhibitors, promotes growth inhibitory effects in oral cancer cells.
Aggarwal S; John S; Sapra L; Sharma SC; Das SN
Cancer Chemother Pharmacol; 2019 Mar; 83(3):451-461. PubMed ID: 30519710
[TBL] [Abstract][Full Text] [Related]
7. The mutation in the ATP-binding region of JAK1, identified in human uterine leiomyosarcomas, results in defective interferon-gamma inducibility of TAP1 and LMP2.
Hayashi T; Kobayashi Y; Kohsaka S; Sano K
Oncogene; 2006 Jul; 25(29):4016-26. PubMed ID: 16474838
[TBL] [Abstract][Full Text] [Related]
8. Combination of all-trans retinoic acid and interferon-gamma suppressed PI3K/Akt survival pathway in glioblastoma T98G cells whereas NF-kappaB survival signaling in glioblastoma U87MG cells for induction of apoptosis.
Zhang R; Banik NL; Ray SK
Neurochem Res; 2007 Dec; 32(12):2194-202. PubMed ID: 17616812
[TBL] [Abstract][Full Text] [Related]
9. Regulation of SHP2 by PTEN/AKT/GSK-3β signaling facilitates IFN-γ resistance in hyperproliferating gastric cancer.
Tseng PC; Huang WC; Chen CL; Sheu BS; Shan YS; Tsai CC; Wang CY; Chen SO; Hsieh CY; Lin CF
Immunobiology; 2012 Sep; 217(9):926-34. PubMed ID: 22325465
[TBL] [Abstract][Full Text] [Related]
10. IFN-gamma regulation of class II transactivator promoter IV in macrophages and microglia: involvement of the suppressors of cytokine signaling-1 protein.
O'Keefe GM; Nguyen VT; Ping Tang LL; Benveniste EN
J Immunol; 2001 Feb; 166(4):2260-9. PubMed ID: 11160280
[TBL] [Abstract][Full Text] [Related]
11. PTEN permits acute increases in D3-phosphoinositide levels following TCR stimulation but inhibits distal signaling events by reducing the basal activity of Akt.
Seminario MC; Precht P; Bunnell SC; Warren SE; Morris CM; Taub D; Wange RL
Eur J Immunol; 2004 Nov; 34(11):3165-75. PubMed ID: 15468057
[TBL] [Abstract][Full Text] [Related]
12. Protein kinase D3 regulates the expression of the immunosuppressive protein, PD‑L1, through STAT1/STAT3 signaling.
Cui B; Chen J; Luo M; Wang L; Chen H; Kang Y; Wang J; Zhou X; Feng Y; Zhang P
Int J Oncol; 2020 Apr; 56(4):909-920. PubMed ID: 32319563
[TBL] [Abstract][Full Text] [Related]
13. miR-144-3p facilitates nasopharyngeal carcinoma via crosstalk with PTEN.
Song L; Chen L; Luan Q; Kong Q
J Cell Physiol; 2019 Aug; 234(10):17912-17924. PubMed ID: 30834525
[TBL] [Abstract][Full Text] [Related]
14. High level class II trans-activator induction does not occur with transient activation of the IFN-gamma signaling pathway.
Eason DD; Blanck G
J Immunol; 2001 Jan; 166(2):1041-8. PubMed ID: 11145683
[TBL] [Abstract][Full Text] [Related]
15. Activation of the MHC class II transactivator CIITA by interferon-gamma requires cooperative interaction between Stat1 and USF-1.
Muhlethaler-Mottet A; Di Berardino W; Otten LA; Mach B
Immunity; 1998 Feb; 8(2):157-66. PubMed ID: 9491997
[TBL] [Abstract][Full Text] [Related]
16. Loss of interferon-gamma inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post-transcriptional as well as epigenetic regulation.
Meissner M; Whiteside TL; van Kuik-Romein P; Valesky EM; van den Elsen PJ; Kaufmann R; Seliger B
Br J Dermatol; 2008 May; 158(5):930-40. PubMed ID: 18284388
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic regulations in the IFNγ signalling pathway: IFNγ-mediated MHC class I upregulation on tumour cells is associated with DNA demethylation of antigen-presenting machinery genes.
Vlková V; Štěpánek I; Hrušková V; Šenigl F; Mayerová V; Šrámek M; Šímová J; Bieblová J; Indrová M; Hejhal T; Dérian N; Klatzmann D; Six A; Reiniš M
Oncotarget; 2014 Aug; 5(16):6923-35. PubMed ID: 25071011
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of IFN-gamma-induced class II transactivator expression by a 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion.
Pai RK; Convery M; Hamilton TA; Boom WH; Harding CV
J Immunol; 2003 Jul; 171(1):175-84. PubMed ID: 12816996
[TBL] [Abstract][Full Text] [Related]
19. Critical role for casein kinase 2 and phosphoinositide-3-kinase in the interferon-gamma-induced expression of monocyte chemoattractant protein-1 and other key genes implicated in atherosclerosis.
Harvey EJ; Li N; Ramji DP
Arterioscler Thromb Vasc Biol; 2007 Apr; 27(4):806-12. PubMed ID: 17255531
[TBL] [Abstract][Full Text] [Related]
20. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.
Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F
Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
